Statins up-regulate SmgGDS through β1-integrin/Akt1 pathway in endothelial cells

Area of Science:

• Cardiovascular Pharmacology
• Molecular Biology
• Cellular Signaling

Background:

• Statins exhibit pleiotropic effects beyond cholesterol reduction.
• Previous studies linked statin pleiotropic effects to SmgGDS up-regulation, Rac1 degradation, and reduced oxidative stress.
• The precise molecular mechanisms underlying statin-induced SmgGDS up-regulation remain unclear.

Purpose of the Study:

• To investigate the tissue-specific effects of statins on SmgGDS expression.
• To elucidate the molecular pathways, particularly the role of Akt1 and β1-integrin, in statin-mediated SmgGDS up-regulation.
• To understand the cellular mechanisms behind statins' non-cholesterol-lowering effects.

Main Methods:

• In vivo studies using atorvastatin and pravastatin in mice to assess SmgGDS expression in various tissues, focusing on the aorta.
• In vitro experiments using cultured human umbilical venous endothelial cells (HUVEC) and human aortic vascular smooth muscle cells.
• Gene silencing techniques (siRNA) to knock down Akt1 and β1-integrin in HUVEC.
• Assessment of Akt phosphorylation and confirmation using an Akt activator (SC79).

Main Results:

• Statins (atorvastatin and pravastatin) significantly increased SmgGDS expression, particularly in the mouse aorta.
• Atorvastatin enhanced SmgGDS expression and Akt phosphorylation in HUVEC but not in vascular smooth muscle cells.
• Knockdown of Akt1 or β1-integrin abolished atorvastatin's effect on SmgGDS up-regulation, while Akt activation by SC79 increased SmgGDS.

Conclusions:

• Statins selectively up-regulate SmgGDS expression in endothelial cells.
• The β1-integrin/Akt1 signaling pathway is critically involved in mediating this statin-induced SmgGDS up-regulation.
• These findings highlight novel molecular mechanisms contributing to the pleiotropic actions of statins.